Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

Similar articles for PubMed (Select 22934534)

1.

Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.

Ko SY, Choe WH, Kwon SY, Kim JH, Seo JW, Kim KH, Lee CH.

Scand J Gastroenterol. 2012 Nov;47(11):1362-7. doi: 10.3109/00365521.2012.719927. Epub 2012 Aug 31.

PMID:
22934534
2.

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.

Gastroenterology. 2012 Sep;143(3):619-28.e1. doi: 10.1053/j.gastro.2012.05.037. Epub 2012 May 27.

PMID:
22643350
3.

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR.

J Viral Hepat. 2012 Mar;19(3):213-9. doi: 10.1111/j.1365-2893.2011.01533.x. Epub 2011 Oct 17.

PMID:
22329376
4.

Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.

Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S.

Dig Dis Sci. 2012 May;57(5):1358-65. doi: 10.1007/s10620-011-1988-0. Epub 2011 Dec 2.

PMID:
22134785
5.

Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.

Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group.

Hepatology. 2011 Aug;54(2):443-51. doi: 10.1002/hep.24406. Erratum in: Hepatology. 2011 Dec;54(6):2280.

PMID:
21563196
6.

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.

Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y.

Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472. Epub 2013 Mar 1.

7.

Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B.

Chon YE, Kim SU, Lee CK, Heo J, Kim JK, Yoon KT, Cho M, Lee KS, Kim DH, Choi EH, Park JY, Kim do Y, Chon CY, Han KH, Ahn SH.

Antivir Ther. 2011;16(4):469-77. doi: 10.3851/IMP1772.

PMID:
21685534
8.

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.

Hepatology. 2010 Feb;51(2):422-30. doi: 10.1002/hep.23327.

PMID:
20049753
9.

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Am J Gastroenterol. 2011 Jul;106(7):1264-71. doi: 10.1038/ajg.2011.45. Epub 2011 Mar 1.

PMID:
21364549
10.

Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.

Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF.

J Gastroenterol Hepatol. 2014 May;29(5):1028-34. doi: 10.1111/jgh.12476.

PMID:
24325451
11.

Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily.

Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH.

J Clin Gastroenterol. 2013 May-Jun;47(5):461-5. doi: 10.1097/MCG.0b013e318266fd31.

PMID:
23090046
12.

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.

Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, Hwang SG, Rim KS, Chon CY, Han KH, Park JY.

Hepatology. 2011 May;53(5):1486-93. doi: 10.1002/hep.24221.

PMID:
21520167
13.

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.

Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O.

Scand J Gastroenterol. 2011 Sep;46(9):1111-7. doi: 10.3109/00365521.2011.584898. Epub 2011 May 30.

PMID:
21623676
14.

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.

Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH.

J Gastroenterol Hepatol. 2013 Jan;28(1):46-50. doi: 10.1111/j.1440-1746.2012.07269.x.

PMID:
22989322
15.

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.

Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.

J Viral Hepat. 2012 Oct;19(10):724-31. doi: 10.1111/j.1365-2893.2012.01599.x. Epub 2012 Mar 15.

PMID:
22967104
16.

Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice.

Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG, Silva MO.

Int J Clin Pract. 2011 Aug;65(8):866-70. doi: 10.1111/j.1742-1241.2011.02719.x.

PMID:
21762311
17.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
18.

Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.

Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK.

J Viral Hepat. 2011 Oct;18(10):e475-81. doi: 10.1111/j.1365-2893.2011.01479.x. Epub 2011 Jun 1.

PMID:
21914066
19.

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.

Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F.

Eur J Gastroenterol Hepatol. 2014 Feb;26(2):146-54. doi: 10.1097/MEG.0b013e328365c3e5.

PMID:
24025974
20.

Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y.

Clin Exp Med. 2012 Sep;12(3):159-64. doi: 10.1007/s10238-011-0160-7. Epub 2011 Oct 15.

PMID:
22002708
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk